FLUIDINOVA SA

Their core work

Fluidinova is a Portuguese SME specializing in the production of synthetic nanoparticles, particularly for biomedical applications such as bone repair and implant materials. They manufacture nanohydroxyapatite and related nanomaterials used in medical devices, dental products, and orthopedic implants. Their H2020 involvement centers on supplying advanced nanoparticle materials to consortia developing next-generation biomaterials, 3D-printed implants, and industrial nanoparticle production monitoring systems. They bridge the gap between nanomaterial synthesis and real-world medical and industrial manufacturing applications.

What they specialise in

How they've shifted over time

Fluidinova's earliest H2020 work (GIOTTO, 2019) focused squarely on biomedical nanomaterials for orthopedic applications — injectable cements, functionalized surfaces, and superparamagnetic nanoparticles for bone repair. By 2020-2021, their focus broadened toward industrial-scale production challenges (NanoPAT's process analytics and photonics-based monitoring) and hybrid multi-material manufacturing for implants (INKplant). This shift suggests a company maturing from a pure materials supplier toward involvement in scalable manufacturing processes and quality control for nanoparticle production.

Fluidinova is moving from supplying nanoparticles for specific medical applications toward mastering scalable, quality-controlled industrial nanoparticle production — positioning themselves as a manufacturing partner, not just a materials supplier.

How they like to work

Fluidinova operates exclusively as a participant, never leading consortia — consistent with an SME that contributes specialized materials expertise rather than managing large projects. With 49 unique partners across just 3 projects, they work in large research consortia (averaging ~16 partners per project), suggesting comfort in complex, multi-partner environments. Their role is that of a specialist contributor bringing proprietary nanoparticle production capabilities to the table.

Despite only 3 projects, Fluidinova has built a broad network of 49 partners across 13 countries, reflecting participation in large European consortia. Their base near Porto positions them within the Iberian research ecosystem with strong pan-European reach.

What sets them apart

Fluidinova occupies a rare niche as an SME that actually manufactures synthetic nanoparticles at scale — most nanomaterial work in H2020 is done by universities, not commercial producers. Their combination of nanoparticle production capability with deep biomedical application knowledge (bone, dental, implants) makes them a valuable industrial partner for any consortium that needs real, producible nanomaterials rather than lab-scale samples. For project coordinators, they offer something hard to find: a private company that can move nanoparticle innovations from research to production.

Highlights from their portfolio

• GIOTTO
  Largest funded project (EUR 237,500), tackling the socially significant challenge of osteoporotic fractures using smart nanobiomaterials and 3D fabrication technologies.
• NanoPAT
  Represents Fluidinova's strategic pivot toward industrial process monitoring, combining photonics with nanoparticle production at scale — their most industry-oriented project.
• INKplant
  Combines multiple advanced manufacturing techniques (inkjet printing, ceramic AM, hybrid manufacturing) for next-generation medical implants, showcasing Fluidinova's cross-disciplinary material contributions.